NeuroBo Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q1 2017 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
NeuroBo Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q1 2017 to Q3 2024.
  • NeuroBo Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 54.6 %, a 53.7% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 54.6 +19.1 +53.7% Sep 30, 2024
Q2 2024 41.2 +2.57 +6.65% Jun 30, 2024
Q1 2024 29.8 -15.2 -33.7% Mar 31, 2024
Q4 2023 30.9 -2.51 -7.51% Dec 31, 2023
Q3 2023 35.5 +19.5 +122% Sep 30, 2023
Q2 2023 38.7 +21.9 +131% Jun 30, 2023
Q1 2023 45 +28.5 +173% Mar 31, 2023
Q4 2022 33.4 +18.6 +126% Dec 31, 2022
Q3 2022 16 -6.17 -27.8% Sep 30, 2022
Q2 2022 16.7 -7.96 -32.3% Jun 30, 2022
Q1 2022 16.5 -11.2 -40.6% Mar 31, 2022
Q4 2021 14.8 -24.6 -62.4% Dec 31, 2021
Q3 2021 22.2 -8.59 -27.9% Sep 30, 2021
Q2 2021 24.7 -83.9 -77.3% Jun 30, 2021
Q1 2021 27.7 +87.5 Mar 31, 2021
Q4 2020 39.3 +60.8 Dec 31, 2020
Q3 2020 30.8 +41.4 Sep 30, 2020
Q2 2020 109 +160 Jun 30, 2020
Q1 2020 -59.8 +910 +93.8% Mar 31, 2020
Q4 2019 -21.5 -148 -117% Dec 31, 2019
Q3 2019 -10.7 -132 -109% Sep 30, 2019
Q2 2019 -50.9 -180 -139% Jun 30, 2019
Q1 2019 -970 -1.07K -1030% Mar 31, 2019
Q4 2018 126 +48.4 +62.4% Dec 31, 2018
Q3 2018 122 +80.6 +197% Sep 30, 2018
Q2 2018 129 +111 +636% Jun 30, 2018
Q1 2018 104 +60.4 +137% Mar 31, 2018
Q4 2017 77.7 Dec 31, 2017
Q3 2017 41 Sep 30, 2017
Q2 2017 17.5 Jun 30, 2017
Q1 2017 44 Mar 31, 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.